Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Other Non Operating Income (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Other Non Operating Income for 3 consecutive years, with -$39000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 165.0% to -$39000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$381000.0 through Dec 2025, down 608.0% year-over-year, with the annual reading at -$381000.0 for FY2025, 608.0% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$39000.0 at Inhibrx Biosciences, up from -$46000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $60000.0 in Q4 2024, with the low at -$246000.0 in Q2 2025.
  • Average Other Non Operating Income over 3 years is -$74181.8, with a median of -$50000.0 recorded in 2025.
  • The sharpest move saw Other Non Operating Income surged 137.97% in 2024, then plummeted 845.45% in 2025.
  • Over 3 years, Other Non Operating Income stood at -$158000.0 in 2023, then soared by 137.97% to $60000.0 in 2024, then crashed by 165.0% to -$39000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$39000.0, -$46000.0, and -$246000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.